Daniel Curcio1, Alejandro Cane2, Francisco Fernández3, Jorge Correa4. 1. Vaccines New Pipeline Medical Lead, Emerging Markets, Pfizer Inc, Buenos Aires. Electronic address: daniel.curcio@pfizer.com. 2. Vaccines Medical and Scientific Affairs Lead Emerging Markets, Pfizer Inc, Buenos Aires. 3. Medical Adviser, Content Medicine, Buenos Aires. 4. Buenos Aires Uniersity, Buenos Aires.
Abstract
BACKGROUND: Surgical site infection (SSI) is both the most frequently studied healthcare-associated infection and the most common healthcare-associated infection in the developing world. A systematic review and meta-analysis was conducted to evaluate the relative size of this burden and to estimate the prevalence of SSI in clean and clean-contaminated surgeries in a large sample of countries in the developing world. METHODS: A systematic search of the MEDLINE/PubMed, Scopus, and LILACS databases was conducted to identify studies providing the prevalence of SSI in elective clean and clean-contaminated surgeries in 39 countries or regions around the world. Data of interest were limited to publications from January 2000 to December 2017. Studies with information on the number of cases of SSI and number of total elective clean and clean-contaminated surgeries during the same period were included in this evaluation. Studies lacking clear definition of the total number of exposed patients were excluded. RESULTS: Based on the combined data from the 99 articles evaluated in this analysis, the overall prevalence of SSI in elective clean and clean-contaminated surgeries was estimated to be 6% (95% confidence interval (CI) 5-7%). This increased to 15% (95% CI 6-27%) when considering only those reports with post-discharge surveillance data. The overall prevalence of SSI in Africa/Middle East, Latin America, Asia, and China was 10% (95% CI 6-15%), 7% (95% CI 5-10%), 4% (95% CI 4-5%), and 4% (95% CI 2-6%), respectively. Significant variability in the data was confirmed by both the funnel plot and the Egger test (p=0.008). CONCLUSIONS: Although the data are variable, it is clear that the incidence of SSI in the developing world is higher than that in the developed world.
BACKGROUND: Surgical site infection (SSI) is both the most frequently studied healthcare-associated infection and the most common healthcare-associated infection in the developing world. A systematic review and meta-analysis was conducted to evaluate the relative size of this burden and to estimate the prevalence of SSI in clean and clean-contaminated surgeries in a large sample of countries in the developing world. METHODS: A systematic search of the MEDLINE/PubMed, Scopus, and LILACS databases was conducted to identify studies providing the prevalence of SSI in elective clean and clean-contaminated surgeries in 39 countries or regions around the world. Data of interest were limited to publications from January 2000 to December 2017. Studies with information on the number of cases of SSI and number of total elective clean and clean-contaminated surgeries during the same period were included in this evaluation. Studies lacking clear definition of the total number of exposed patients were excluded. RESULTS: Based on the combined data from the 99 articles evaluated in this analysis, the overall prevalence of SSI in elective clean and clean-contaminated surgeries was estimated to be 6% (95% confidence interval (CI) 5-7%). This increased to 15% (95% CI 6-27%) when considering only those reports with post-discharge surveillance data. The overall prevalence of SSI in Africa/Middle East, Latin America, Asia, and China was 10% (95% CI 6-15%), 7% (95% CI 5-10%), 4% (95% CI 4-5%), and 4% (95% CI 2-6%), respectively. Significant variability in the data was confirmed by both the funnel plot and the Egger test (p=0.008). CONCLUSIONS: Although the data are variable, it is clear that the incidence of SSI in the developing world is higher than that in the developed world.
Authors: Carlo Luca Romanò; Lorenzo Drago; Hernán Del Sel; Ashok Johari; Guenter Lob; Andreas F Mavrogenis; Thami Benzakour Journal: Int Orthop Date: 2020-05-25 Impact factor: 3.075
Authors: K Morikane; P L Russo; K Y Lee; M Chakravarthy; M L Ling; E Saguil; M Spencer; W Danker; A Seno; E Edmiston Charles Journal: Antimicrob Resist Infect Control Date: 2021-04-01 Impact factor: 4.887